Meehan, G. R. , Scales, H. E. , McInnes, I. B. , Brewer, J. M. and Garside, P. (2022) Orally administered antigen can reduce or exacerbate pathology in an animal model of inflammatory arthritis dependent upon the timing of administration. Immunotherapy Advances, 2(1), ltac020. (doi: 10.1093/immadv/ltac020) (PMID:36268500) (PMCID:PMC9579813)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
278321.pdf - Published Version Available under License Creative Commons Attribution. 13MB |
Abstract
Currently, treatments for rheumatoid arthritis (RA) are focussed on management of disease symptoms rather than addressing the cause of disease, which could lead to remission and cure. Central to disease development is the induction of autoimmunity through a breach of self-tolerance. Developing approaches to re-establish antigen specific tolerance is therefore an important emerging area of RA research. A crucial step in this research is to employ appropriate animal models to test prospective antigen specific immunotherapies. In this short communication, we evaluate our previously developed model of antigen specific inflammatory arthritis in which OVA-specific T cell receptor (TCR) transgenic T cells drive breach of tolerance to endogenous antigens to determine the impact that the timing of therapy administration has upon disease progression. Using antigen feeding to induce tolerance we demonstrate that administration prior to articular challenge results in a reduced disease score as evidenced by pathology and serum antibody responses. By contrast, feeding antigen after initiation of disease had the opposite effect and resulted in the exacerbation of pathology. These preliminary data suggest that the timing of antigen administration may be key to the success of tolerogenic immunotherapies. This has important implications for the timing of potential tolerogenic therapies in patients.
| Item Type: | Articles |
|---|---|
| Additional Information: | This work was supported by funding from the Innovative Medicines Initiative 2 Joint Undertaking [Grant No 777357]. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. www.imi.europa.eu. HES was funded by the University of Glasgow. |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | McInnes, Professor Iain and Garside, Professor Paul and Brewer, Professor James and Scales, Dr Hannah and Meehan, Dr Gavin |
| Authors: | Meehan, G. R., Scales, H. E., McInnes, I. B., Brewer, J. M., and Garside, P. |
| Subjects: | Q Science > QR Microbiology > QR180 Immunology |
| College/School: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Virus Research |
| Research Centre: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology |
| Research Group: | LIVE |
| Journal Name: | Immunotherapy Advances |
| Publisher: | Oxford University Press |
| ISSN: | 2732-4303 |
| ISSN (Online): | 2732-4303 |
| Published Online: | 13 September 2022 |
| Copyright Holders: | Copyright © 2022 The Authors |
| First Published: | First published in Immunotherapy Advances 2(1): ltac020 |
| Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information